MAGE-A4ᶜ¹º³²T for Multi-Tumor (NCT03132922)
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
🩺 Plain-English Summary (8th-Grade Level)
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
Who can join: Review the eligibility criteria below.
Location: University of Miami — Miami, Florida
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells (GENETIC)
- Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation (RADIATION)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (11 Sites)
- University of Miami — Miami, Florida
- Moffitt Cancer Center — Tampa, Florida
- Washington University School of Medicine — St Louis, Missouri
- Washington University — St Louis, Missouri
- Roswell Park Cancer Institute — Buffalo, New York
- Duke University Medical Center, Duke Cancer Institute — Durham, North Carolina
- Ohio State University Wexner Medical Center — Columbus, Ohio
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
- Tennessee Oncology - Sarah Cannon Research Institute — Nashville, Tennessee
- M.D. Anderson Cancer Center — Houston, Texas
- Princess Margaret Cancer Centre — Toronto, Ontario
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Urinary Bladder Cancer
- Intravesical Gem/Doce in Patients With NMIBC — Tucson, Arizona
- SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma — New Brunswick, New Jersey
Explore by condition: All Urinary Bladder Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.